Korea Institute of Science and Technology

Korea Advanced Institute of Science and Technology

Lg Energy Solution, Ltd.

Orient Bio., Inc.

Daesoo Kim

Youngdeok Kim

Hyunjun Choi

Sukchan Lee

Hee-Sup Shin

Youngsoo Kim

Ki Young Chang

Hyunah Choo

ChangJoon Justin Lee

Chanki Kim

Jungryun Lee

Hyeyeon Park

Ji Yoon Kim

Boeun Yoon

Soonwook Choi

Sehoon Keum

Inseon Song

Heesup Shin

Hae-Young Koh

Seonmi Jo

Minju Jeong

Young Gyun Park

Jeongjin Kim

Suwon Jee

The present disclosure relates to a method of recovering a degenerated lithium battery cell, with the lithium battery cell being configured so that an electrode assembly including a positive electrode, a negative electrode and a separator interposed therebetween is impregnated with a non-aqueous electrolyte and embedded in a battery case, the method including: subjecting a lithium battery cell degenerated by 5% or more to a high temperature treatment for 1 to 6 hours at a temperature ranging from 60° C. to 100° C. in a fully discharged state.

Method for recovering lithium battery cell by heat treatment and method for manufacturing lithium battery cell comprising the same

The present disclosure relates to a method for manufacturing a lithium secondary battery comprising the steps of:

Manufacturing method of lithium secondary battery comprising additional heat-treatment process and lithium secondary battery manufactured by the same

The present invention relates to a method for treating Parkinson's disease. According to this method, a halorhodopsin protein, a polynucleotide encoding the halorhodopsin protein or a vector containing the polynucleotide above is introduced into ventrolateral thalamus (VL) or medial globus pallidus (GPm) neurons of a subject having Parkinson's disease. The VL neurons are then illuminated with green light or exposed to a T type Cachannel blocker to inhibit rebound firing of VL neurons. By inhibiting rebound firing of VL neurons, Parkinson's disease can be treated or prevented.

Methods for treating Parkinson's disease

A pharmaceutical composition for preventing or treating a degenerative brain disease, and a method of screening a material for preventing or treating a degenerative brain disease. The method may effectively screen a prophylactic or therapeutic candidate material for preventing or treating a degenerative brain disease. A variety of degenerative brain diseases may be effectively prevented or treated using the pharmaceutical composition including a screened material for preventing or treating a degenerative brain disease.

Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same

Disclosed herein are an &#x3b1;1/CaV3.1 double knockout mouse or &#x3b1;1; Emx1-Cre mouse with enhanced essential tremor and a screening method of therapeutic agents for essential tremor by using the same. The &#x3b1;1/CaV3.1 double knockout mouse or &#x3b1;1; Emx1-Cre mouse of the present invention may be usefully used for development of therapeutic agents for essential tremor because the mouse exhibits essential tremor strong and evident enough to be visually confirmed, compared to an &#x3b1;1 knockout mouse.

Mouse models with enhanced essential tremor and preparation method thereof

The present invention relates to a novel use of an &#x3b1;1G T-type calcium channel transgenic mouse as a nervous disease model, more particularly, a novel use of a mouse deficient in &#x3b1;1G T-type calcium channel showing novelty-seeking and alcohol preference as a nervous disease model for human nervous related diseases such as novelty-seeking character, alcoholism, anxiety and emotion disorder by stress, etc. The &#x3b1;1G T-type channel transgenic mice showing novelty-seeking and alcohol preference of the present invention can be effectively used for the development of a medicine and a therapeutic method for human nervous diseases.

Mice lacking alpha 1G showing enhanced novelty-seeking and alcohol preference and therapeutic methods for mood disorders by modulating alpha 1G T-type calcium channels

The disclosure concerns a method for resistance of epilepsy by suppressing the function of alpha 1G protein of T-type calcium channels, use of suppressor of alpha 1G protein for prevention or treatment for epilepsy, knockout mice resisting epilepsy by disrupting alpha 1G subunit of T-type calcium channel, and preparation method thereof. The &#x3b1;1G-knockout transgenic mouse can be used for investigating the relationship between diseases particularly neuropathy or psychopathy and the function of &#x3b1;1G T-type calcium channel via various behavioral tests since &#x3b1;1G subunit is mainly expression in central nervous system (CNS) and pheripheral nervous system (PNS). Further, the &#x3b1;1G-knockout transgenic mouse can be used for screening antileptic agents.

Transgenic mouse whose genome comprises a homozygous disruption of its &#x3b1;1G gene, a method of preparing the same and use thereof

The present invention relates to a method for screening therapeutic drugs of schizophrenia using an animal model of the disease. More specifically, this invention relates to a screening method based on the phospholipase C &#x3b2;1 (PLC&#x3b2;1) knockout mouse as an animal model of schizophrenia with all the major symptoms of the human disease. This knockout mouse exhibits symptoms similar to human schizophrenia such as locomotor hyperactivity, impaired prepulse inhibition of the startle response, lack of barbering and nesting behaviors, socially subordinate status, impaired learning, and lack of type II theta rhythm which has been implicated in working memory. Thus, the knockout mouse of the present invention can be useful as an animal for screening therapeutic drugs against schizophrenia.

Phospholipase C &#x3b2;1 (PLC&#x3b2;1) knockout mice as a model system for testing schizophrenia drugs

Growing community of inventors

Daejeon, South Korea

Daesoo Kim